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    Recently, we encounter several articles regarding urinary 
trypsin inhibitor (UTI) published nationally [1,2]. When we take 
a glance at these articles, it feels like UTI acts as a miraculous 
medicine on patients under general anesthesia because of 
its protection effect against surgical stress. Yet, even after the 
first report on antitryptic action of urine by Bauer and Reich 
III in 1909 [3]; the start of use of the term UTI by Astrup and 
Sterndorff in 1955 [4]; and numerous animal experiments and 
clinical research done about UTI (803 articles about UTI and 
982 articles about ulinastatin in SCOPUS), UTI is not yet to 
be used commonly. Therefore, it is important to understand 
the reason behind this situation. According to the webpage of 
Nextbio, it records that “currently, the drug is being used for 
research purpose only.”
    UTI is a glycoprotein stable in both heat and acids derived 
from human urine, and is a serine protease inhibitor found 
in human urine or blood. UTI is secreted when inter-α-trypsin 
inhibitors are degraded by neutrophilic elastase [5]. UTI is found 
to have many physiologic effects, including the inhibition of 
neutrophilic elastase, trypsin, α -chymotrypsin, plasmin, and 
cathepsin G. It has been known for a long time [3] and called 
ulinastatin, mingin, human inhibitor 30, serpin, miraclid, 
urinastatin (in japanese literature) and bikunin [6]. It has been 
reported that, in human, the plasma half-life of UTI is 33 min [7]. 
Currenlty, there are three pharmaceutical companies in Korea 
that produce UTI: Ulistin
Ⓡ, Han Lim Pharmaceutical, Ustatin
Ⓡ, 
Kolon Pharmaceutical, Statin
Ⓡ, Yu Young Pharmaceutical. These 
three companies produce two types of UTI, which is 50,000 IU 
(9,962-14,650 won) and 100,000 IU (14,926-21,950 won). 
    Trypsin inhibitors act to suppress the proteolytic action 
of trypsin on a variety of tissues and exert a localized anti-
inflammatory effect [8]. Therefore UTI is indicated for acute 
inflammatory disorders, including acute pancreatitis, systemic 
inflammatory reaction syndrome, circulatory insufficiency, 
Stevens-Johnson syndrome, Toxic epidermal necrolysis (TEN), 
disseminated intravascular coagulation (DIC) and multiple 
organ failure [9]. Previous studies of UTI have focused mainly 
on modulating inflammatory reaction. UTI attenuates the 
elevation of neutrophil elastase release, thereby blunting the 
rise of pro-inflammatory cytokine level; however, the actual 
mechanism in vivo is not clear [10]. In twenty years, lately, 
there has been an increase in the number of reports that 
UTI inhibits secretion of cytokines (IL-6 and IL-8) regarding 
inflammation. Regardless of such fact, there was an additional 
report in this issue on how UTI influences cytokine reactions 
during gastrectomy [1]. This addition of one more report maybe 
because of the fact that UTI’s clinical usage is yet limited and 
the usage has not been standardized for the real practice. In this 
issue of KJA, Park and co-workers [1] reported that 100,000 U of 
UTI infusion during gastrectomy inhibited the secretion of IL-
6, which is an inflammatory cytokine produced after operation. 
They showed that UTI could decrease the inflammatory 
reaction caused by surgical stress. 
    In addition to UTI’s effect on inflammation, there has been a 
lot of studies of influence of UTI on shock. In 1985, Ohnishi et 
al. [11] proved that UTI lowers the elevated enzyme activities 
in the serum during shock so that UTI has protective effect 
against shock in his animal experiment. There also has been 326 www.ekja.org
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a study that UTI is effective in maintaining microcirculation 
during hemodilution and hypothermia [12]. UTI’s anti-shock 
effect was as effective as that of methyl prednisolone (MPS); 
both substances showed similar effects in endotoxin-induced 
shock animal experiments [13]. MPS showed effect when after 
the shock occurred, whereas UTI showed effect when injected 
prophylactically [14]. Recently, there was a clinical research 
that the combined usage of UTI and Thymosin alpha1 (Talph1) 
increased the survival rate of sever sepsis patients [15-17], 
which proves UTI’s usefulness as a potential medicine. 
    A study about the hemostatic effects of ulinastatin in clinical 
practice was demonstrated in our journal three months ago 
[2]. Lee et al. [2] concluded that a single infusion of ulinastatin 
during major orthopedic surgery reduces blood loss in the early 
postoperative period. UTI inhibit proinflammatory cytokine 
release, reduce reperfusion lung injury and preserve pulmonary 
function but it failed to inhibit platelet activation and to prevent 
blood loss during CPB [18]. 
    There were studies about UTI’s effect on liver, lung, heart, 
small intestine, pancreas, uterine muscle etc. UTI is important 
in liver regeneration [19], can protect against sever liver injury 
[20], and decreases reperfusion injury after hepatic ischemia 
[21]. High dose of UTI inhibits pulmonary fibrosis by decreasing 
inflammatory response in lungs [22] and also has protective 
effect against ischemia/reperfusion injury in lungs. Also, the 
cardioprotective effect decreases the infarct size in patients 
with the regional myocardial I/R injury [23]. When UTI is used 
preventively, pancreatitis occurring frequencies decrease and, 
through the regulation of intracellular calcium, UTI suppresses 
the uterine muscle contraction. It furthermore suppresses 
activity of plasminogen activator, which leads to improvements 
in joint pain and range of motion in osteoarthritis patients [24].
    Saitoh reported contents regarding anesthetic drugs in 
UTI studies; in neuromuscular junctions, protease inhibitor 
homologs release acetylcholine which results in delay of onset 
of neuromuscular block by vecuronium and accelerates the 
recovery [25]. Mastumoto explained that UTI increases the 
blood flow in liver [26], so it promotes hepatic elimination of 
vecuronium and increases urine volume [27]. Because UTI 
may increase hepatic and/or renal clearance of vecuronium, 
recovery of vecuronium-induced neuromuscular block would 
be quickened.
    As shown above, UTI will be useful if its various effects are 
proven clinically and its dose and ways usage are standardized 
accurately. When used in case of general anesthesia in high-risk 
patients, UTI can better the microcirculation during circulatory 
insufficiency which can potentially occur during the operation; 
therefore, UTI can better the perfusion for main organs and 
decrease the inflammatory response so that post-surgical 
progress can be improved, pain be reduced, and mobidity be 
reduced also. However, UTI’s effect on skeletal muscle relaxants 
used in general anesthesia should be considered. Also due to its 
comparative high cost, we should avoid reckless and indiscrete 
usage.
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